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Abstract
Background: Early in life, patients with cystic fibrosis (CF) are infected with microorganisms including bacteria and fungi,
particularly Pseudomonas aeruginosa and Aspergillus fumigatus. Since recent research has identified the anti-inflammatory
properties of statins (besides their lipid-lowering effects), we investigated the effect of fluvastatin on the production of the
potent neutrophil chemoattractant chemokine, IL-8, in whole blood from CF patients, stimulated by Pseudomonas
aeruginosa (LPS) and Aspergillus fumigatus (AFA) antigens.
Results: Whole blood from adult patients with CF and from healthy volunteers was collected at the Rennes University
Hospital (France). Blood was pretreated for 1 h with fluvastatin (0–300 mM) and incubated for 24 h with LPS (10 mg/mL)
and/or AFA (diluted 1/200). IL-8 protein levels, quantified by ELISA, were increased in a concentration-dependent manner
when cells were stimulated by LPS or AFA. Fluvastatin strongly decreased the levels of IL-8, in a concentration-dependent
manner, in whole blood from CF patients. However, its inhibitory effect was decreased or absent in whole blood from
healthy subjects. Furthermore, the inhibition induced by fluvastatin in CF whole blood was reversed in the presence of
intermediates within the cholesterol biosynthesis pathway, mevalonate, farnesyl pyprophosphate or geranylgeranyl
pyrophosphate that activate small GTPases by isoprenylation.
Conclusions: For the first time, the inhibitory effects of fluvastatin on CF systemic inflammation may reveal the important
therapeutic potential of statins in pathological conditions associated with the over-production of pro-inflammatory
cytokines and chemokines as observed during the manifestation of CF. The anti-inflammatory effect could be related to the
modulation of the prenylation of signalling proteins.
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Introduction
Cystic fibrosis (CF) is a multisystem disease during which
systemic inflammation is more prolonged and pronounced than in
many other chronic diseases. This inflammation results, in part,
from an overproduction of pro-inflammatory cytokines from chro-
nically infected lungs to the central circulation [1]. In particular,
defects in cystic fibrosis transmembrane conductance regulator
(CFTR) are associated with an increased production of interleukin
(IL)-8, a potent neutrophil chemoattractant that stimulates a
massive influx of neutrophils into the airways [2]. Interrupting the
vicious cycle of infection and inflammation is effective in slowing
the course of the disease and antibiotics have long been the staple
of pulmonary therapy. Besides the anti-infective strategy, high
dose ibuprofen, resulting in an anti-inflammatory effect, delayed
the progression of lung disease but was responsible for adverse
events that limited its therapeutic utility [3,4]. A possible
therapeutic intervention may be based on the neutralisation of
cytokines and chemokines, such as tumor necrosis factor (TNF)-a,
IL-1b and IL-8, with specific antibodies, receptor antagonists or
inhibition of the intracellular signalling cascades that result in their
production. However, alternative anti-inflammatory agents are
necessary.
Statins are 3-hydroxy-3-methyl-glutaryl–coenzyme-A (HMGCoA)
reductase inhibitors that have been used clinically as lipid lowering
agents and have an established role in the treatment of athero-
sclerotic disease. However statins do more than just lower
cholesterol [5]. Recent research has identified the anti-inflamma-
tory properties of statins [6,7]. These effects have been related to the
prevention of the prenylation of signalling molecules with sub-
sequent downregulation of pro-inflammatory gene expression [8].
Furthermore, it was shown that statins also reduce the stability of
lipid raft formation with subsequent effects on immune activation
and regulation [9]. Both effects resulted in reduced cytokines,
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chemokines and adhesion molecule expression [10]. The findings in
a recent systemic review and meta-analysis show a possible
association between statin treatment and reduced mortality rate
after having been diagnosed with bacterial infections [11]. Recently
a retrospective clinical analysis showed that simvastatin use was
associated with a significant decrease in the rate of forced expiratory
volume in one second (FEV1) and forced vital capacity (FVC)
decline in smokers and non-smokers with airflow obstruction [12].
Indeed, recent studies have reported the therapeutic effect of statins
in lung inflammatory diseases, such as in chronic obstructive
pulmonary disease (COPD) [13], in asthma [14] and in acute lung
injury [15,16]. However, no study has evaluated the potential
therapeutic interest of statins during CF.
Human immune cell lines only partially reflect the responses of
primary cells. As blood of healthy donors and patients is easily
accessible, numerous studies have been carried out employing
isolated human peripheral blood cells. However, the highly sen-
sitive leukocytes are easily affected and/or modulated by
purification and isolation procedures. Ex vivo stimulation of whole
blood appears to reflect closely what happens in vivo. Therefore the
simple approach of employing human whole blood as an isolated
organ is used to monitor immune function ex vivo [17,18,19].
The objective of this study was to investigate the anti-
inflammatory effects of fluvastatin in reducing the circulating
levels of IL-8 in an ex vivo model of human whole blood from
patients with CF compared to healthy subjects. The fluvastatin
inhibition was studied after stimulation with Pseudomonas aeruginosa
and Aspergillus fumigatus antigens, alone or in combination. Finally,
we examined whether fluvastatin inhibited whole blood IL-8
secretion through isoprenylation-dependent mechanisms. This
work considers, for the first time, the important therapeutic
potential of statins in pathological conditions associated with
chronic inflammation such as those that occur in CF.
Methods
Ethics statement
This study was conducted according to the Good Clinical
Practice guidelines and approved by the Ethical Committee of
human subjects of the university hospital of Rennes, France (Ethics
No. 07/32-649).
Patients with CF
All patients included in this study gave their written informed
consent. Twenty three stable adult patients with CF were recruited
at the ‘Centre de Ressources et de Compe´tences de la Mucoviscidose’
(CRCM) of the Rennes University Hospital (France). Patients with
CF considered for inclusion were Caucasian, 14 males and 9
females, aged between 18–44 years (mean age: 2968). The CF
diagnosis was based on typical clinical manifestations of the disease
and confirmed by positive sweat tests and by CFTR gene mutation
detection. The stable patients were defined by the absence of
change in their symptoms in the 3 months prior to the study. All
the patients with CF had medication at the time of blood
collection, including azithromycin, aerosol of DNAse, inhaled
corticosteroids and azole therapy. Patients who were chosen were
not on oral corticosteroids therapy, as this may have impaired
inflammatory stimulation at the time of blood collection, and this
may have influenced results. The clinical features of these patients
are described in Table 1.
Healthy volunteers
Healthy subjects included as controls were Caucasian, 4 males
and 6 females, aged between 20–48 years (mean age: 31611).
They were healthy as determined by medical history, without
personal history of CF or other significant illness, with a non-
smoking status and were recruited from amongst the staff of respi-
ratory department of the Rennes University Hospital (France).
Experimental protocol
For each subject, 15 mL of whole blood was collected in heparin-
tubes. Blood was aliquoted into 96-well microplates, under sterile
conditions and incubated for 30 min at 37uC in an atmosphere of
5% CO2 and 95% air [19].
Pre-treatment with increasing concentrations of fluvastatin
(0.01–300 mM) or vehicle were incubated for 1 h. At the end of
this incubation period, Pseudomonas aeruginosa (LPS) and/or
Aspergillus fumigatus (AFA) antigens were added into stimulated
wells whereas unstimulated wells received a sterile saline vehicle
only (NaCl 0.9%). To study the reversion of fluvastatin inhibition,
mevalonate (416 mM) or the isoprenoids, farnesyl pyrophosphate
(FPP, 10 mM) and geranylgeranyl pyrophosphate (GGPP, 10 mM)
were added to fluvastatin during the 1 h pre-treatment. Reversion
Table 1. Demographic data expressed as numbers (number
of patients in groups, genotype, medication, extrapulmonary
diseases and infectious colonization, with percentage in
brackets) or median (age, BMI, FEV1 and FCV, with range in
brackets).
Parameters Demographic data
Number of patients (males) 23 (14)
Median age in years 29 (18–44)
BMI (kg.m22) 20 (15–24.5)
blood neutrophils count (61029/L) 5.5 (2.1–12.8)




no F508del 4 (17%)
Pulmonary function tests
FEV1, % predicted 68 (30–114)
FVC, % predicted 88 (46–125)
Medication
Azithromycin 3 (14%)
DNAse aerosol 12 (55%)
Inhaled corticosteroids 15 (65%)
Azole therapy 9 (39%)
Extrapulmonary diseases
Pancreatic insufficiency 17 (77%)
Liver disease 5 (23%)
Diabetes 6 (27%)
Infectious colonization
Pseudomonas aeruginosa 16 (70%)
Staphylococcus aureus 19 (83%)
Aspergillus fumigatus 14 (61%)
All data were assessed at the time of sample collection. Blood neutrophils and
monocytes count are not significantly different in CF patients group (one-way
ANOVA, Kruskal-Wallis test).
Abbreviations: BMI, Body mass index; FEV1, Forced expiratory volume in one
second; FVC, Forced vital capacity.
doi:10.1371/journal.pone.0022655.t001
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studies were performed with blood from five CF patients (2 with
homozygous F508del mutation, 2 with heterozygous F508del
mutation and 1 with other mutations) and five healthy volunteers
from amongst the subjects recruited. After 24 h of stimulation the
supernatants were gently transferred into polypropylene micro-
tubes and stored at 280uC until the IL-8 assay was performed.
Measurement of IL-8 release
IL-8 levels were quantified from diluted blood samples
according to the manufacturer’s instructions (PeproTech, Tebu-
Bio, Le Perray en Yvelines, France). A human IL-8 standard
concentration-response curve was run on each microplate to allow
determination of IL-8 levels in samples. IL-8 concentrations in
each sample were determined using an automatic plate reader
associated with Genesis software (LabSystems Spectrophotometer,
Cambridge, UK) and data were expressed in ng/mL.
Materials
Fluvastatin was acquired from Calbiochem (Merck Chemicals,
Nottingham, UK), dissolved in sterile distilled water at a
concentration of 5 mM and then diluted as required with sterile
saline (NaCl 0.9%). LPS from Pseudomonas aeruginosa, mevalonate
(mevalonic acid 5-phosphate trilithium salt hydrate), farnesyl
pyrophosphate ammonium salt (FPP) and geranylgeranyl pyro-
phosphate ammonium salt (GGPP) were obtained from Sigma (St.
Louis, MO, USA). FPP and GGPP in methanol:ammonium
solution (7:3) were diluted in sterile saline. Soluble antigens from
Aspergillus fumigatus (AFA) were provided from Bio-Rad Laborato-
ries (Marnes-la-Coquette, France). They were dissolved in 1 mL
sterile distilled water and then diluted using NaCl 0.9%.
Statistical analysis
The number of subjects used in each group is stated in the
respective figure legends. All graphs are expressed as mean 6
SEM. IC50 values were calculated using regression analysis from
dose-reponse curves (GraphPad Prism5 software, San Diego,
USA). Statistical analyses were performed on the data and IC50
values using one-way ANOVA Kruskal-Wallis test or non-
parametric Mann–Whitney test as appropriate (GraphPad Prism5
software). P,0.05 was considered to be statistically significant.
Results
Patients characteristics
Twenty three CF patients (14 male and 9 female subjects) were
recruited for the study (Table 1). Lung function and microbiolog-
ical testing were performed in all patients. According to the FEV1
values (% predicted), the majority of our patients (17/23) had mild
to moderate lung disease (respectively FEV1 values$55% of
predicted values). Seventeen patients were affected by pancreatic
insufficiency. Sixteen patients had microbiological evidence of
Pseudomonas aeruginosa colonization and fourteen of Aspergillus
fumigatus. The blood leukocytes count for CF patients was within
normal range with a median number of 5.56109/L (range 2.1–
12.86109/L) for neutrophils and of 0.646109/L (range 0.32–
1.106109/L) for monocytes.
Antigens from Pseudomonas aeruginosa and Aspergillus
fumigatus increase IL-8 production
Basal levels of IL-8 in whole blood from CF patients
(27416467 pg/mL, n= 23) were three times higher than those
measured in blood from healthy volunteers (8726515 pg/mL,
n= 10, p,0.05) (Fig. 1).
IL-8 levels were raised in a concentration-dependent manner
when whole blood was stimulated with increasing concentrations
of antigens from Pseudomonas aeruginosa (LPS) or from Aspergillus
fumigatus (AFA) (not shown). The concentration of 10 mg/mL of
LPS and the 1/200 dilution of AFA, which had induced a
significant production of IL-8, were further used to assess the
inhibitory effects of fluvastatin (Fig. 1). The LPS-induced level of
IL-8 reached 51.868.2 ng/mL (n= 10) for healthy subjects and
80.269.9 ng/mL (n= 23) for CF patients. In whole blood from
healthy subjects and CF patients, AFA induced the release of IL-8
to 113.6627.2 ng/mL (n= 4) and 227.1639.7 ng/mL (n= 23),
respectively.
When both AFA and LPS were used in combination to
stimulate whole blood, there were no additional increases of IL-8
production compared that of each antigen alone (Fig. 1).
Fluvastatin inhibits IL-8 secretion in whole blood from CF
patients
Without stimulation, fluvastatin from 0.01 mM significantly
inhibited IL-8 basal levels in whole blood from CF patients but
had no significant effect on whole blood from healthy subjects
(Fig. 2). Maximal inhibition of IL-8 production by fluvastatin was
observed at 30 mM with an efficacy value of 56.764.2% and an
IC50 value of 13.165.3 mM (Table 2).
From 0.01 mM, fluvastatin also decreased IL-8 production when
whole blood from CF patients was stimulated with LPS (Fig. 3B)
whereas a concentration of 30 mM was necessary to significantly
inhibit IL-8 production in whole blood from healthy subjects
(Fig. 3A). Fluvastatin was four times more potent in inhibiting
LPS-induced IL-8 secretion in whole blood from CF patients than
in healthy volunteers, with respective IC50 values being
4.661.0 mM and 19.167.4 mM (Table 2). However, the same
maximal inhibition of LPS-induced IL-8 production was observed
in CF patients and healthy volunteers (61.864.5% and 60.76
8.2% at 100 mM, respectively).
When inflammatory stimulation was induced by AFA in whole
blood from CF patients fluvastatin produce a significant inhibitory
effect from 10 mM whereas no significant effect was observed in
Figure 1. Pseudomonas aeruginosa and Aspergillus fumigatus
antigens stimulation of IL-8 production. Pseudomonas aeruginosa
(LPS, 10 mg/mL) and/or Aspergillus fumigatus (AFA, 1/200) antigens were
added in the whole blood from 4 to 10 healthy subjects (open bars) and
23 CF patients (solid bars and grey bar for co-stimulation) for 24 h. After
incubation, IL-8 release (ng/mL) was measured by ELISA. Data are
shown as mean 6 SEM. Mann and Whitney test: *P,0.05, *** P,0.0001
vs basal; 1 P,0.05 vs healthy patients.
doi:10.1371/journal.pone.0022655.g001
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AFA-stimulated whole blood from healthy volunteers (Fig. 4).
Fluvastatin was more potent in inhibiting IL-8 release in CF
patients than in healthy subjects, with IC50 values being
33.1615.0 mM and .300 mM respectively (Table 2). In this
context, fluvastatin induced an unchanged maximal inhibition of
IL-8 production in whole blood from CF patients and healthy
subjects (27.169.1% and 27.564.4% at 100 mM respectively).
Isoprenoids and mevalonate reverse fluvastatin
inhibition
To characterize the statin target, individual components of the
HMG-CoA reductase pathway, schematically shown in Fig. 5A,
were combined with fluvastatin. The inhibitory effect of 10 mM
fluvastatin on LPS-stimulated IL-8 release was reversed by
mevalonate supplement (416 mM) or isoprenoids, FFP (10 mM)
and GGPP (10 mM) supplements (Fig. 5B). By contrast, the
inhibitory effect of fluvastatin was not reversed in the whole blood
from healthy subjects (Fig. S1).
CFTR mutation influences basal IL-8 release in whole
blood from CF patients
The concentration of IL-8 release in whole blood was dependent
on CF mutations (Fig. 6). Significantly higher IL-8 levels were
observed in the F508del mutation group (n= 4) compared to the
groups with homozygous (n= 11) or heterozygous F508del
mutation (n= 8). No significant difference between mutation groups
was observed when whole blood was stimulated with LPS
(83.11611.9 ng/mL, 80.2623.0 ng/mL and 71.9618.7 ng/mL
for homozygous, heterozygous F508del and no F508del mutation
group, respectively). In contrast, regarding IL-8 secretion, the
homozygous F508del group seemed to be more sensitive to AFA
stimulation (274.9678.1 ng/mL) than the heterozygous F508
Figure 2. Fluvastatin inhibition of basal IL-8 production. Whole
blood from healthy volunteers (A, n = 10) and from CF patients (B,
n = 23) were treated with fluvastatin (0.01–300 mM, 1 h). After
incubation, IL-8 release (ng/mL) was measured by ELISA. Data are
shown as mean6 SEM. Mann and Whitney test: *P,0.05, ** P,0.001 vs
without fluvastatin (0).
doi:10.1371/journal.pone.0022655.g002
Table 2. IC50 values of fluvastatin (mM) calculated using







Basal .300 mM 13.165.3 mM
LPS-induced 19.167.4 mM 4.661.0 mM**
AFA-induced .300 mM 33.1615.0 mM
Values are means 6 SEM. Mann and Whitney test:
**P,0.001 vs healthy volunteers.
doi:10.1371/journal.pone.0022655.t002
Figure 3. Fluvastatin inhibition of LPS-induced IL-8 production.
Whole blood from healthy volunteers (A, n = 10) and from CF patients
(B, n = 23) were pre-treated with fluvastatin (0.01–300 mM, 1 h) and
incubated with Pseudomonas aeruginosa antigens (LPS, 10 mg/mL) for
24 h. After incubation, IL-8 release (ng/mL) was measured by ELISA.
Data are shown as mean 6 SEM. Mann and Whitney test: *P,0.05,
** P,0.001, *** P,0.0001 vs without fluvastatin (0).
doi:10.1371/journal.pone.0022655.g003
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group (178.08636.1 ng/mL) or the F508del mutation group
(193.67617.9 ng/mL).
There was no observed difference on the inhibitory effect of
fluvastatin between the various CFTR mutations groups. The only
detectable difference between these 3 groups of patients, based on
the CFTR mutation, was the frequency of the liver disease: 36% of
the F508del homozygous group had liver disease vs 0% in the 2
other groups.
Discussion
This study showed that Pseudomonas aeruginosa and Aspergillus
fumigatus antigens induce IL-8 secretion in whole blood from CF
patients and healthy volunteers. Basal and antigen-induced IL-8
releases were more inhibited by fluvastatin in CF patients than in
healthy subjects and this effect was reversed in the presence of
isoprenoids or mevalonate.
CF inflammation results from a complex combination of
inflammatory processes due to the disease but also to recurrent
infections. Bacteria and fungi are responsible for acute and chronic
colonization and/or infection and thus represent important co-
factors for local and systemic inflammation. Aspergillus fumigatus, the
causative agent of allergic bronchopulmonary aspergillosis
(ABPA), and Pseudomonas aeruginosa, particularly the mucoid strains,
have been frequently isolated from the sputum of patients with CF
[20]. When exposed to Aspergillus fumigatus or LPS, immune and
pulmonary epithelial cells respond with increased synthesis and
increased release of TNF-a, IL-1b, IL-8 and IL-6 [19,21,22].
These pro-inflammatory cytokines can further activate neutrophils
and lymphocytes, initiating cellular injury and tissue damage [23].
Among them, IL-8 has an important role in neutrophil elastase-
induced goblet cell metaplasia and the production of Muc5ac in
airway epithelium [24]. In CF, elevated levels of IL-8 in sputum
result in chronic infection, neutrophilic inflammation and
progressive airway destruction. Furthermore whole blood IL-8
levels were related to the severity of CF [25]. As expected, when
whole blood was stimulated with Pseudomonas aeruginosa or/and
Aspergillus fumigatus antigens we observed a strong increase in IL-8
release that was not enhanced by co-stimulation. IL-8 levels were
Figure 4. Fluvastatin inhibition of AFA-induced IL-8 produc-
tion. Whole blood from healthy volunteers (A, n = 4) and from CF
patients (B, n = 23) were treated with fluvastatin (0.01–300 mM, 1 h) and
incubated with Aspergillus fumigatus antigens (AFA, 1/200) for 24 h.
After incubation, IL-8 release (ng/mL) was measured by ELISA. Data are
shown as mean 6 SEM. Mann and Whitney test: *P,0.05 vs without
fluvastatin (0).
doi:10.1371/journal.pone.0022655.g004
Figure 5. Reversion of fluvastatin inhibition by metabolite of 3-
hydroxy-3-methylglutaryl-CoA (HMG-CoA). (A) Diagram summa-
rizing HMG-CoA reductase pathway and the effect of statins. (B)
Mevalonate (416 mM, 1 h) and isoprenoids, farnesyl pyrophosphate
(FPP, 10 mM, 1 h) and geranylgeranyl pyrophosphate (GGPP, 10 mM,
1 h) reversed inhibitory effect of fluvastatin (10 mM, 1 h) on IL-8
production stimulated by LPS from Pseudomonas aeruginosa (LPS,
10 mg/ml, 24 h) in the whole blood from 5 CF patients. Data are shown
as mean 6 SEM. Mann and Whitney test: *P,0.05 vs LPS stimulation.
doi:10.1371/journal.pone.0022655.g005
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three times higher in CF patients than in healthy subjects
confirming excessive systemic inflammation in CF. Enhanced
expression of TLR4 in monocytes from children with clinically
stable CF was also recently demonstrated. Toll-like receptors
(TLRs), of which TLR2 and TLR4 on the cell surface of leukocytes
are important in relation to host defense against pathogens trigger
signalling pathways that activate NF-kB and transcription of pro-
inflammatory cytokines and IL-8 [25]. A significant increase in IL-8
in the whole blood assay is an interesting finding, with regard to
previous research. The few studies performed were not able to
provide evidence of a significant correlation between serum IL-8
and clinical status of the patient [26,27], and Kronborg et al. (1993)
[28] found only low or non-detectable levels of circulating cytokines
in plasma. The differences between those results and our findings
can be explained by the fact that cytokines are active compounds in
plasma, rapidly bound to their soluble receptor and then neutralized
[29,30]. Taking this into account, plasma is not a good source for
measuring the host’s propensity to secrete cytokines. This problem
can be overcome by using the whole blood assay where inhibitory
factors are reduced by dilution with saline and cultured mononu-
clear cells constantly secrete cytokines in the supernatant. The
immune cells are present in natural ratios and can interact with each
other allowing considering whole blood as an isolated organ. As no
isolation procedure beyond the drawing of blood is required, the
assay is characterized by few preparation artifacts and standardized
performance. Volunteers are not exposed directly to potentially
hazardous agents such as lipopolysaccharide (LPS) as in the case of
human experimental endotoxemia, yet information about immune
modulation under conditions of leukocyte activation or over-
activation can be obtained [31]. The advantage of using whole
blood is the exclusion of secondary changes of the cells in the
intensely inflamed environment of the CF airway that might have
an influence on final results. Apparently, the human organism has to
control the responsiveness of its leukocytes very carefully: any
hyporesponsiveness will result in infectious complications and any
hyperresponsiveness in inflammatory disorders. A major concern
against whole blood models is the interindividual variation in
leukocyte numbers. In fact, in healthy donors the normal range of
leukocyte numbers is within a fairly tight window, between 4.5 and
116109/L. As previously observed [32], the blood leukocytes count
for stable CF patients was within normal range.
Statins are a class of cholesterol-lowering drugs that decrease
the mortality of cardiovascular diseases [33]. However their
therapeutic potential also relies on anti-inflammatory effects.
Several chronic lung inflammatory diseases seem to be improved
by statins, as reported in asthma [14], COPD [13], acute lung
injury, sepsis and infection [16,34,35]. There are also reports that
the statins can inhibit T and B cell activation, prevent inflam-
matory responses and block activation of leukocyte subsets
[10,36,37,38,39]. Furthermore, protection by simvastatin includes
the inhibition of host cell invasion by Staphylococcus aureus due in
part to depletion of isoprenoid intermediates within the cholesterol
biosynthesis pathway [40]. In addition, the modulation of
neutrophilic apoptosis, as observed under statin treatment [41],
may prove beneficial in chronic inflammatory lung diseases such
as CF, during which neutrophil numbers are significantly in-
creased in airways [2]. Neutrophilia associated with acute lung
injury in a mouse model was markedly reduced after treatment
with lovastatin [42]. Mucus hypersecretion in the respiratory tract
also contributes to airway inflammation, particularly during CF.
Ou et al. (2008) [43] have demonstrated that simvastatin attenuates
airway mucus hypersecretion and pulmonary inflammatory
damage induced by LPS, in rats. Also, lovastatin has recently
been shown to inhibit human alveolar epithelial production of IL-
8 [44]. Furthermore, the outcomes in lung transplantation were
compared between patients treated with statins for hyperlipidae-
mia and untreated controls. Acute rejection was less frequent;
bronchoalveolar lavage showed lower total cellularity as well as
lower numbers of neutrophils and lymphocytes, and survival was
91% compared with 54% in controls [45]. This raises the
intriguing possibilities of the therapeutic interest of statin in lung
transplanted CF patients. However at present, no study has
investigated this potential therapeutic interest of statins in CF.
It has recently emerged that different families of statins may
have various anti-inflammatory properties [34]. Kiener et al. (2001)
[46] showed that lipophilic statins such as atorvastatin, simvastatin
and fluvastatin have a much greater effect on the inflammatory
response in human and mouse models than the hydrophilic,
pravastatin. Furthermore fluvastatin has a very potent hypocho-
lesterolemic effect with fewer adverse effects than other HMG-
CoA reductase inhibitors [47]. In addition to its lipophilic and
anti-inflammatory properties, fluvastatin also has the advantage of
not requiring activation prior to its use for in vitro studies and it
does not present toxicity in leukocytes (Fig. S2) [47]. In our study,
fluvastatin (from 0.01 mM) inhibits IL-8 release from whole blood
cells of CF patients in different conditions including in unstimu-
lated cells, those stimulated by antigens from Pseudomonas aeruginosa
or, with lesser effect, by soluble antigens from Aspergillus fumigatus.
The efficacy of fluvastatin was unchanged in whole blood from all
subjects whereas its IC50 was four times lesser in CF patients than
in healthy volunteers. This suggests an improved pharmacological
profile in terms of in vitro efficacy and potency, and thus a potential
increased therapeutic index. This attenuation of LPS-induced
inflammation was previously observed with simvastatin in a
randomized double-blind placebo-controlled clinical study involv-
ing healthy volunteers challenged with LPS aerosols [48].
However, we have observed a better effect of fluvastatin in whole
blood from CF patients compared with healthy volunteers. Indeed,
while TLRs expression is enhanced in CF monocytes [25],
fluvastatin dose-dependently inhibits monocyte TLR4 and TLR2
expressions in whole blood from patients with chronic heart failure
[49].
Figure 6. Basal IL-8 level and CF Mutations. CFTR mutations
influence IL-8 basal secretion in whole blood from CF patients. Number
of patients per group according to CFTR mutation is in brackets. Data
are shown as mean 6 SEM. Mann and Whitney test: ** P,0.001 vs
F508del homozygous group; 1 P,0.05 vs F508del heterozygous group.
doi:10.1371/journal.pone.0022655.g006
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Besides the reduction of cholesterol biosynthesis, through
competitive inhibition of the enzyme HMG-CoA reductase, the
current hypothesis for the pleiotropic effect favours the inhibition
of isoprenoid biosynthesis as the likely mechanism. The mevalo-
nate synthetic pathway mediated by HMG-CoA reductase is
crucial for the biosynthesis of isoprenoids, which are essential for
normal cellular inflammatory signalling. Farnesylpyrophosphate is
a later intermediate on this pathway and serves as a precursor for
the synthesis of various isoprenoids - for example, geranylgeranyl
or farnesyl groups - which prenylate proteins through covalent
links [8]. These can anchor prenylated proteins to lipid rafts and
many of them play important roles in the regulation of cell growth,
cell secretion, and signal transduction. Thus, by inhibiting
prenylation, statins should affect many cell processes involved in
inflammation. In our model of whole blood from CF patients,
isoprenoids reversed the inhibition of LPS-stimulated IL-8 pro-
duction suggesting that fluvastatin acts by preventing the
prenylation of signalling molecules, such as rho-A, ras or rac,
implicated in IL-8 signalling [50]. Increased rhoA expression and
activation was demonstrated in CF cells [51] and may explain that
reversion is only observed in whole blood from CF patients and
not in healthy subjects.
Finally, we have observed that patients with the non-F508del
mutation show higher basal levels of IL-8 than homo- or
heterozygous F508del mutation. Little research has studied the
phenotypic consequences of CFTR mutations [52,53]. Our results,
which should be confirmed on a larger patient cohort, suggest that
the CFTR genotype may be involved in whole blood IL-8 release
related to systemic inflammation in CF patients. However, we
could not find a significant difference in IL-8 production after
stimulation with LPS or AFA in any of the CF mutation groups.
Therefore enhanced IL-8 secretion after induced acute inflamma-
tion in whole blood from CF patients may not related to CFTR
genotype.
In conclusion, fluvastatin inhibits basal Pseudomonas aeruginosa
and Aspergillus fumigatus antigen-induced IL-8 secretion in whole
blood from CF patients through an isoprenylation-dependent
mechanism. The inhibitory effects of fluvastatin on systemic
inflammation may reveal the important therapeutic potential of
statins in various pathological conditions associated with the over-
production of pro-inflammatory cytokines and chemokines as
observed in CF.
Supporting Information
Figure S1 No reversion of fluvastatin inhibition by
metabolite of HMG-CoA in whole blood from healthy
volunteers. Mevalonate (416 mM, 1 h) and isoprenoids, farnesyl
pyrophosphate (FPP, 10 mM, 1 h) and geranylgeranyl pyrophos-
phate (GGPP, 10 mM, 1 h) have not reversed inhibitory effect of
fluvastatin (10 mM, 1 h) on IL-8 production stimulated by LPS
from Pseudomonas aeruginosa (LPS, 10 mg/ml, 24 h) in the whole
blood from 5 healthy subjects. Data are shown as mean 6 SEM.
(TIF)
Figure S2 MTT assay was used to determine viability of
cells treated with fluvastatine. Human leukocytes from
healthy subjects obtained fom Ficoll gradient were seeded into 24-
well plates at a density of 46106 per well and treated with
fluvastatin at 0.01 to 100 mM (1 h), alone or in the presence of
Pseudomonas aeruginosa antigens (LPS, 10 mg/ml, 24 h). Wells with
vehicle (NaCl 0.9%) were used as negative control. At 1 h before
each of the desired time points, 100 ml of MTT solution (5 mg/ml
in PBS, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, Sigma, La Verpillie`re, France) was added into each well and
cells were incubated at 37uC and 5% CO2 for another 2 h. The
medium was removed and 100 ml of DMSO was added into each
well. The plate was gently rotated on an orbital shaker for 10 min to
completely dissolve the precipitation. The absorbance was detected
at 570 nm with a microplate reader associated with Genesis
software (LabSystems Spectrophotometer, Cambridge, UK).
(TIF)
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